Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Lang

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Gynecologic Oncology Reports|April 24, 2025
Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancerSusan M Lang, Filippos Vingopoulos, Isabel Beshar, et al.
JCI Insight|March 23, 2018
Endothelial cell Pannexin1 modulates severity of ischemic stroke by regulating cerebral inflammation and myogenic toneMiranda E Good, Stephanie A Eucker, Jun Li, et al.
Gynecologic Oncology|June 23, 2022
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancerCarlotta Keunecke, Hagen Kulbe, Felix Dreher, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Gynecologic Oncology Reports|April 24, 2025
Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancerSusan M Lang, Filippos Vingopoulos, Isabel Beshar, et al.
JCI Insight|March 23, 2018
Endothelial cell Pannexin1 modulates severity of ischemic stroke by regulating cerebral inflammation and myogenic toneMiranda E Good, Stephanie A Eucker, Jun Li, et al.
Gynecologic Oncology|June 23, 2022
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancerCarlotta Keunecke, Hagen Kulbe, Felix Dreher, et al.
Pageof 2